Taltz
Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis
August 15, 2019Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis
Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
December 18, 2018Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …
Lilly posts promising P3 Taltz data
February 14, 2018Research and Development Cosentyx, Eli Lilly, IL-17, Novartis, Taltz, biotech, drugs, pharma, pharmaceutical
The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …
Eli Lilly’s Taltz get EU approval in psoriatic arthritis subgroup
January 24, 2018Research and Development, Sales and Marketing EU, Eli Lilly, Europe, European Commission, Taltz, pharma, psoriatic arthritis
Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …
Lilly posts impressive psoriasis results in comparison study
March 6, 2017Research and Development, Sales and Marketing J&J, JJ, Stelara, Taltz, lilly
Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. …
FDA approves Lilly’s plaque psoriasis drug Taltz
March 23, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …
CHMP recommends Lilly psoriasis drug for approval
February 29, 2016Research and Development Eli Lilly, Taltz, psoriasis
Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
